These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22731929)

  • 1. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
    Quan WD; Quan FM; Perez M; Johnson E
    Cancer Biother Radiopharm; 2012 Sep; 27(7):442-5. PubMed ID: 22731929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
    Quan W; Knupp C; Quan F; Walker P
    Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
    Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
    Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
    Quan WD; Quan FM; King LA; Walker PR
    Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Apr; 24(2):181-3. PubMed ID: 19409039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
    Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
    Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
    Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
    Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
    Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
    Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
    Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
    Quan WD; Gagnon GA; Walker PR; Quan FM
    Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma.
    Quan W; Brick W; Vinogradov M; Taylor WC; Khan N; Burgess R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):350-4. PubMed ID: 15285881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.
    Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Dean G; Moore J; Bradley EC
    Bull N Y Acad Med; 1989 Jan; 65(1):128-44. PubMed ID: 2532554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].
    Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Bradley EC
    J Clin Oncol; 1988 Mar; 6(3):409-24. PubMed ID: 2965219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
    Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
    Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.